
Lupin completes acquisition of US-based Gavis Pharmaceuticals
pharmafile | March 10, 2016 | News story | Research and Development, Sales and Marketing | FDA, Gavis, Lupin, acquisition, generics
Indian drug manufacturer Lupin has announced the completion of its acquisition of New Jersey-based pharmaceutical firm, Gavis, in a deal worth $880 million.
As reported previously, the deal will see Lupin enhance its presence in the US generic market, with access to Gavis’ 62 generic drugs, which the firm has already filed to the FDA for approval.
72% of these ANDA filings pending approval requests represent niche dosage forms with 18 Para IVs and eight FTFs products. The existing pending approvals of Gavis address a market of over $9 billion.
Vinita Gupta, chief executive officer at Lupin, comments: “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as speciality pipeline.”
Sean Murray
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Alto Neuroscience’s schizophrenia treatment granted FDA Fast Track designation
Alto Neuroscience has announced that its investigational treatment for cognitive impairment associated with schizophrenia (CIAS) …

FDA approves Moderna’s updated COVID-19 vaccines targeting new variant
The US Food and Drug Administration (FDA) has approved Moderna’s updated COVID-19 vaccines, Spikevax and …






